Radboud university medical center
Nijmegen, Gelderland, 6525 GA, Netherlands
NCT Number: NCT03923114
The main goal is the comparison of pituitary uptake of Ga-68-NODAGA-exendin-4 in patients with and without adequate response (based on HbA1c or weight loss) to GLP-1R agonist treatment.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Nijmegen, Gelderland, 6525 GA, Netherlands
The prevalence of type 2 diabetes (T2D) is increasing and a better understanding of the mechanisms of T2D becomes increasingly important. The glucagon-like peptide 1 receptor agonists (GLP-1RA), such as exendin, can be used as potent antidiabetic drugs for treatment of T2D. Not all patients with T2D respond to treatment with GLP-1RA and some even respond with contradictory effects, but the underlying mechanism for this observation remains unclear. Interestingly, uptake of an exendin-based radiotracer was observed in the pituitary gland in diabetes patients. In this study, the effect of GLP-1RA on the HPA axis will be further studied for an improved understanding of the mechanisms and contradictory treatment responses.
Patient data will be obtained and will consist of metabolic characterization (laboratory parameters and oral glucose tolerance test), an ACTH assay and determination of cortisol excretion. In addition, Ga-68-NODAGA-exendin-4 PET/CT imaging will be performed in 10 patients with treatment response (decrease in HbA1c or weight loss) and 10 patients without response after GLP-1RA therapy. In 5 patients with high radiotracer uptake, an additional brain MRI scan will be performed for improved anatomical referencing.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients with treatment response:
Patients without treatment response:
Exclusion criteria
PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
Time frame: 1.5 year
Comparison of the pituitary uptake (Bq) of Ga-68-NODAGA-exendin-4 obtained by quantitative analysis
Time frame: 1.5 year
Assessment of the metabolic status by performing an OGTT (mmol/l)
Time frame: 1.5 year
Assessment of the metabolic status by performing an ACTH assay (mol/l)
Radboud University Medical Center
Other
iPAVE - Imaging Pituitary ActiVation by Exendin
Acronym: iPAVE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04828785
Diabetes Mellitus, Diabetes Mellitus, Type 2
Chapel Hill, North Carolina, United States
View Trial DetailsNCT07019649
Diabetes Mellitus, Diabetes Mellitus, Type 2
Pleasanton, California, United States
View Trial DetailsNCT01878045
Diabetes Complications, Diabetes Mellitus
Phoenix, Arizona, United States
View Trial DetailsNCT02840630
Diabetes Mellitus, Diabetes Mellitus, Type 2
Aberdeen, United Kingdom
View Trial Details